{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "## Import Library\n",
    "\n",
    "import openai\n",
    "from azure.core.credentials import AzureKeyCredential\n",
    "from azure.identity import AzureDeveloperCliCredential\n",
    "from azure.search.documents import SearchClient\n",
    "from azure.search.documents.indexes import SearchIndexClient\n",
    "from azure.search.documents.indexes.models import (\n",
    "    HnswParameters,\n",
    "    PrioritizedFields,\n",
    "    SearchableField,\n",
    "    SearchField,\n",
    "    SearchFieldDataType,\n",
    "    SearchIndex,\n",
    "    SemanticConfiguration,\n",
    "    SemanticField,\n",
    "    SemanticSettings,\n",
    "    SimpleField,\n",
    "    VectorSearch,\n",
    "    VectorSearchAlgorithmConfiguration,\n",
    ")\n",
    "from azure.storage.blob import BlobServiceClient\n",
    "\n",
    "import openai\n",
    "import os\n",
    "from langchain.embeddings.openai import OpenAIEmbeddings\n",
    "from langchain.vectorstores.azuresearch import AzureSearch\n",
    "\n",
    "import openai\n",
    "import os\n",
    "from langchain.embeddings.openai import OpenAIEmbeddings\n",
    "from langchain.vectorstores.azuresearch import AzureSearch\n",
    "\n",
    "from azure.storage.blob import BlobServiceClient\n",
    "from azure.core.exceptions import ResourceExistsError\n",
    "import json\n",
    "\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain.chains.question_answering import load_qa_chain\n",
    "#from langchain.retrievers import AzureCognitiveSearchRetriever\n",
    "from langdetect import detect\n",
    "from langchain.prompts import PromptTemplate\n",
    "import re\n",
    "# Create chain to answer questions\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain.chains.question_answering import load_qa_chain\n",
    "from langchain.memory import ConversationBufferMemory\n",
    "from langchain.prompts import PromptTemplate\n",
    "from langchain.chains import LLMChain\n",
    "\n",
    "# Import Azure OpenAI\n",
    "from langchain.llms import AzureOpenAI \n",
    "from langchain.chat_models import AzureChatOpenAI\n",
    "from langchain.schema import HumanMessage\n",
    "\n",
    "#import textwrap\n",
    "import logging\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "\"\"\"#setting up credentials\n",
    "os.environ[\"AZURE_COGNITIVE_SEARCH_SERVICE_NAME\"] = \"gptdemosearch\" # replace with yours search service name\n",
    "os.environ[\"AZURE_COGNITIVE_SEARCH_API_KEY\"] = \"PcAZcXbX2hJsxMYExc2SnkMFO0D94p7Zw3Qzeu5WjYAzSeDMuR5O\" # replace with your api key\n",
    "os.environ[\"AZURE_INDEX_NAME\"] = \"sino-hr-chatbot\" #\"namfung-finance-chatbot\" # \n",
    "# end setting up credentials\"\"\"\n",
    "\n",
    "# setting up credentials\n",
    "os.environ[\"AZURE_COGNITIVE_SEARCH_SERVICE_NAME\"] = \"acs-fda-paid\" # replace with yours search service name\n",
    "os.environ[\"AZURE_COGNITIVE_SEARCH_API_KEY\"] = \"VZhK9GGzAJ625kSvDXUpBo1CmiIfH6Ou64EDhoiSczAzSeADco5j\" # replace with your api key\n",
    "os.environ[\"AZURE_INDEX_NAME\"] = \"fda-index\" #\"namfung-finance-chatbot\" # \n",
    "# end setting up credentials\n",
    "\n",
    "#Free version of acs\n",
    "#index_name = \"your-index-name\"\n",
    "#search_service = \"acs-testing-sunny\"\n",
    "#search_api_key = \"oygYftyrBXiWoDLoZatDKNSLFttn9frM6DE4XlSb7kAzSeBR01eY\"\n",
    "\n",
    "#Paid version of acs\n",
    "#index_name = \"fda-index\"\n",
    "#search_service = \"acs-fda-paid\"\n",
    "#search_api_key = \"VZhK9GGzAJ625kSvDXUpBo1CmiIfH6Ou64EDhoiSczAzSeADco5j\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "def generate_prompt():\n",
    "    prompt_template_string=\"\"\"\n",
    "    Follow exactly these 5 steps:\n",
    "    1. Read the context below and aggregrate this data\n",
    "    Context : {context}\n",
    "    2. Answer the question using only this context\n",
    "    3. Answer the question in less than 200 words\n",
    "    4. Please provide the page number of the page where your answer is based on \n",
    "    5. Please provide the page number in the following output format: [Page: 1]\n",
    "    \n",
    "    User Question: {question}\n",
    "\n",
    "\n",
    "    If you don't have any context and are unsure of the answer, reply that you don't know about this topic.\n",
    "    \"\"\"\n",
    "    prompt_template = PromptTemplate(template = prompt_template_string, input_variables=[\"context\", \"question\"])\n",
    "\n",
    "    return prompt_template\n",
    "\n",
    "def generate_prompt_chi():\n",
    "    prompt_template_string=\"\"\"\n",
    "    指令：\n",
    "    1. 你必须只根据以下文本的内容回答提问者的询问。\n",
    "    2. 如果不懂得回答或文本没有资料，请回答“对不起，我不懂得回答这个问题。”\n",
    "    3. 请以少於200字回答问题。\n",
    "    4. 请在你的回答后提供你用以回答的文本的页数。格式示例：[Page: 1]\n",
    "    \n",
    "    文本：{context}\n",
    "    #####\n",
    "\n",
    "    问题：{question}\n",
    "\n",
    "    \"\"\"\n",
    "    prompt_template = PromptTemplate(template = prompt_template_string, input_variables=[\"context\", \"question\"])\n",
    "\n",
    "    return prompt_template\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "def initialize_vector_store():\n",
    "    # set up index name \n",
    "    index_name = os.environ[\"AZURE_INDEX_NAME\"] \n",
    "    \n",
    "    # set up openai environment\n",
    "    os.environ[\"OPENAI_API_TYPE\"] = \"azure\"\n",
    "    os.environ[\"OPENAI_API_BASE\"] = \"https://pwcjay.openai.azure.com/\"\n",
    "    os.environ[\"OPENAI_API_VERSION\"] = \"2023-05-15\"\n",
    "    os.environ[\"OPENAI_API_KEY\"] = \"f282a661571f45a0bdfdcd295ac808e7\"\n",
    "\n",
    "    model: str = \"text-embedding-ada-002\"\n",
    "    search_service = os.environ[\"AZURE_COGNITIVE_SEARCH_SERVICE_NAME\"]\n",
    "    search_api_key = os.environ[\"AZURE_COGNITIVE_SEARCH_API_KEY\"]\n",
    "    vector_store_address: str = f\"https://{search_service}.search.windows.net\"\n",
    "    vector_store_password: str = search_api_key\n",
    "    \n",
    "\n",
    "    # define embedding model for calculating the embeddings\n",
    "    model: str = \"text-embedding-ada-002\"\n",
    "    embeddings: OpenAIEmbeddings = OpenAIEmbeddings(deployment=model, chunk_size=1)\n",
    "    embedding_function = embeddings.embed_query\n",
    "\n",
    "    # define schema of the json file stored on the index\n",
    "    fields = [\n",
    "            SimpleField(\n",
    "                name=\"id\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                key=True,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            SearchableField(\n",
    "                name=\"content\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            SearchField(\n",
    "                name=\"content_vector\",\n",
    "                type=SearchFieldDataType.Collection(SearchFieldDataType.Single),\n",
    "                searchable=True,\n",
    "                vector_search_dimensions=len(embedding_function(\"Text\")),\n",
    "                vector_search_configuration=\"default\",\n",
    "            ),\n",
    "            SearchableField(\n",
    "                name=\"metadata\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            # Additional field to store the title\n",
    "            SearchableField(\n",
    "                name=\"title\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"source\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"page\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"website_url\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "        ]    \n",
    "    \n",
    "    vector_store: AzureSearch = AzureSearch(\n",
    "        azure_search_endpoint=vector_store_address,\n",
    "        azure_search_key=vector_store_password,\n",
    "        index_name=index_name,\n",
    "        embedding_function=embedding_function,\n",
    "        fields=fields,\n",
    "    )\n",
    "    \n",
    "    return vector_store"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [],
   "source": [
    "def azure_search_by_index(question, index_name):\n",
    "\n",
    "    # set up openai environment\n",
    "    os.environ[\"OPENAI_API_TYPE\"] = \"azure\"\n",
    "    os.environ[\"OPENAI_API_BASE\"] = \"https://pwcjay.openai.azure.com/\"\n",
    "    os.environ[\"OPENAI_API_VERSION\"] = \"2023-05-15\"\n",
    "    os.environ[\"OPENAI_API_KEY\"] = \"f282a661571f45a0bdfdcd295ac808e7\"\n",
    "\n",
    "    model: str = \"text-embedding-ada-002\"\n",
    "    search_service = os.environ[\"AZURE_COGNITIVE_SEARCH_SERVICE_NAME\"]\n",
    "    search_api_key = os.environ[\"AZURE_COGNITIVE_SEARCH_API_KEY\"]\n",
    "    vector_store_address: str = f\"https://{search_service}.search.windows.net\"\n",
    "    vector_store_password: str = search_api_key\n",
    "    \n",
    "\n",
    "    # define embedding model for calculating the embeddings\n",
    "    model: str = \"text-embedding-ada-002\"\n",
    "    embeddings: OpenAIEmbeddings = OpenAIEmbeddings(deployment=model, chunk_size=1)\n",
    "    embedding_function = embeddings.embed_query\n",
    "\n",
    "    # define schema of the json file stored on the index\n",
    "    fields = [\n",
    "            SimpleField(\n",
    "                name=\"id\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                key=True,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            SearchableField(\n",
    "                name=\"content\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            SearchField(\n",
    "                name=\"content_vector\",\n",
    "                type=SearchFieldDataType.Collection(SearchFieldDataType.Single),\n",
    "                searchable=True,\n",
    "                vector_search_dimensions=len(embedding_function(\"Text\")),\n",
    "                vector_search_configuration=\"default\",\n",
    "            ),\n",
    "            SearchableField(\n",
    "                name=\"metadata\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            # Additional field to store the title\n",
    "            SearchableField(\n",
    "                name=\"title\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"source\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"page\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"website_url\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "        ]    \n",
    "    \n",
    "    vector_store: AzureSearch = AzureSearch(\n",
    "        azure_search_endpoint=vector_store_address,\n",
    "        azure_search_key=vector_store_password,\n",
    "        index_name=index_name,\n",
    "        embedding_function=embedding_function,\n",
    "        fields=fields,\n",
    "    )\n",
    "\n",
    "    relevant_documentation = vector_store.similarity_search(query=question, k=1, search_type=\"similarity\")\n",
    "    \n",
    "    context = \"\\n\".join([doc.page_content for doc in relevant_documentation])[:10000]\n",
    "\n",
    "    lang = detect(context)\n",
    "\n",
    "    #print(doc)\n",
    "    #print(context)\n",
    "    #print(relevant_documentation)\n",
    "    source = relevant_documentation[0].metadata['source']\n",
    "    page_no = relevant_documentation[0].metadata['page']\n",
    "    website_url = relevant_documentation[0].metadata['website_url']\n",
    "    \n",
    "    page_no = \"\"\n",
    "    for doc in relevant_documentation:\n",
    "        page_no = page_no + \",\" + doc.metadata['page'] \n",
    "    \n",
    "    #print(relevant_documentation[0])\n",
    "    #print(source)\n",
    "    #print(page_no)\n",
    "    #print(website_url)\n",
    "    #return str(context), source, website_url, lang, page_no\n",
    "    # just return 10 documents (i.e. pages) if number of pages return from the search result > 10\n",
    "    if len(relevant_documentation) > 10:\n",
    "        relevant_documentation = relevant_documentation[0:9]\n",
    "    else:\n",
    "        relevant_documentation = relevant_documentation\n",
    "    return relevant_documentation, source, website_url, lang, page_no\n",
    "\n",
    "\n",
    "# helper function to extract page number\n",
    "def extract_page_no(string):\n",
    "    if \"[Page\" in string:\n",
    "        print(re.findall('\\[Page:.*\\]', string)[0].split('Page:')[1])\n",
    "        return re.findall('\\[Page:.*\\]', string)[0].split(':')[1].split(\"]\")[0].strip()\n",
    "    else:\n",
    "        return \"/\"\n",
    "\n",
    "def extract_answer(string):\n",
    "    if \"[Page\" in string:\n",
    "        return string.split(\"[Page\")[0]\n",
    "    else:\n",
    "        return string\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.chains import LLMChain\n",
    "from langchain.llms import AzureOpenAI \n",
    "from langchain.memory import ConversationBufferMemory\n",
    "from langchain.prompts import PromptTemplate\n",
    "from langchain.chat_models import AzureChatOpenAI\n",
    "from langchain.memory import CosmosDBChatMessageHistory\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [],
   "source": [
    "def generate_prompt_with_history():\n",
    "    prompt_template_string=\"\"\"\n",
    "    Follow exactly these 6 steps:\n",
    "    1. Read the context below and aggregrate this data\n",
    "    Context : {context}\n",
    "    2. Answer the question using only this context and the chat history below\n",
    "    3. Answer the question in less than 200 words\n",
    "    4. Please provide the page number of the pages where your answer are based on at the end of your response\n",
    "    5. Please provide the page numbers in the following output format: [Page: 1, 2, 3...]\n",
    "    6. Allow the chat continue by following Chat History\n",
    "    \n",
    "    Chat History: {chat_history}\n",
    "\n",
    "    User Question: {question}\n",
    "\n",
    "\n",
    "    If you don't have any context and are unsure of the answer, reply that you don't know about this topic.\n",
    "    \"\"\"\n",
    "    prompt_template = PromptTemplate(template = prompt_template_string, input_variables=[\"context\", \"question\", \"chat_history\"])\n",
    "\n",
    "    return prompt_template\n",
    "\n",
    "def generate_prompt_chi_with_history():\n",
    "    prompt_template_string=\"\"\"\n",
    "    指令：\n",
    "    1. 你必须只根据以下文本的内容及谈话记录回答提问者的询问。\n",
    "    2. 如果不懂得回答或文本没有资料，请回答“对不起，我不懂得回答这个问题。”\n",
    "    3. 请以少於200字回答问题。\n",
    "    4. 请在你的回答后提供你用以回答的文本的页数。格式示例：[Page: 1, 2, 3...]\n",
    "    5. 通过谈话记录允许聊天继续\n",
    "    \n",
    "    文本：{context}\n",
    "\n",
    "    谈话记录：{chat_history}\n",
    "\n",
    "    #####\n",
    "\n",
    "    问题：{question}\n",
    "\n",
    "    \"\"\"\n",
    "    prompt_template = PromptTemplate(template = prompt_template_string, input_variables=[\"context\", \"question\", \"chat_history\"])\n",
    "\n",
    "    return prompt_template\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.chains import ConversationalRetrievalChain\n",
    "\n",
    "# helper function to extract page number\n",
    "def extract_page_no(string):\n",
    "    if \"[Page\" in string:\n",
    "        print(re.findall('\\[Page:.*\\]', string)[0].split('Page:')[1])\n",
    "        return re.findall('\\[Page:.*\\]', string)[0].split(':')[1].split(\"]\")[0].strip()\n",
    "    elif \"(Page:\" in string: # handling for exception\n",
    "        print(re.findall('\\(Page:.*\\)', string)[0].split('Page:')[1])\n",
    "        return re.findall('\\(Page:.*\\)', string)[0].split(':')[1].split(\")\")[0].strip()\n",
    "    else:\n",
    "        return \"/\"\n",
    "\n",
    "def extract_answer(string):\n",
    "    if \"[Page\" in string:\n",
    "        return string.split(\"[Page\")[0]\n",
    "    else:\n",
    "        return string\n",
    "\n",
    "def llm_pipeline_with_history(question):\n",
    "    # set up index name \n",
    "    index_name = os.environ[\"AZURE_INDEX_NAME\"] \n",
    "\n",
    "    os.environ[\"OPENAI_API_TYPE\"] = \"azure\"\n",
    "    os.environ[\"OPENAI_API_VERSION\"] = \"2023-05-15\"\n",
    "    os.environ[\"OPENAI_API_BASE\"] = \"https://pwcjay.openai.azure.com/\"\n",
    "    os.environ[\"OPENAI_API_KEY\"] = \"f282a661571f45a0bdfdcd295ac808e7\"\n",
    "\n",
    "\n",
    "    # retrieve information from Azure Search\n",
    "    relevant_docs, source, website_url, language, page_no = azure_search_by_index(question, index_name)\n",
    "\n",
    "    language = detect(question)\n",
    "\n",
    "    if language == \"cn\":\n",
    "    #Chinese prompt\n",
    "        QA_CHAIN_PROMPT = generate_prompt_chi_with_history()\n",
    "    else:\n",
    "        QA_CHAIN_PROMPT = generate_prompt_with_history()\n",
    "\n",
    "    # use AzureChatOpenAI \n",
    "    llm = AzureChatOpenAI(deployment_name=\"gpt-35-16k\", temperature=0,\n",
    "                        openai_api_version=\"2023-05-15\", openai_api_base=\"https://pwcjay.openai.azure.com/\")\n",
    "\n",
    "\n",
    "    \"\"\"    # set up chat history database credentials\n",
    "    os.environ[\"COSMOS_ENDPOINT\"] = \"https://gpt-demo-chat-history.documents.azure.com:443/\"\n",
    "    os.environ[\"COSMOS_KEY\"] = \"AZEhMpW4YD3t7iEMgp9at48S7f5ZjvnahUqJMYjMjMpH2QH2wiYBL97RdX7AqL3CMQcGGhbdAFHvACDbDDwMyA==\"\n",
    "    ENDPOINT = os.environ[\"COSMOS_ENDPOINT\"]\n",
    "    KEY = os.environ[\"COSMOS_KEY\"]\n",
    "    DATABASE_NAME = \"sino_demo\"\n",
    "    CONTAINER_NAME = \"sino_chat_history\"\"\"\n",
    "    \n",
    "    # set up chat history database credentials\n",
    "    os.environ[\"COSMOS_ENDPOINT\"] = \"https://acs-testing-sunny.documents.azure.com:443/\"\n",
    "    os.environ[\"COSMOS_KEY\"] = \"UyxAxYPy6nhqLoTVhbs7C8NknhHoaRJuFkBaZramSAEPzNsHU0dhanOTRr2AJOjtqA1m0d5N3ujkACDbNmxrAQ==\"\n",
    "    ENDPOINT = os.environ[\"COSMOS_ENDPOINT\"]\n",
    "    KEY = os.environ[\"COSMOS_KEY\"]\n",
    "    DATABASE_NAME = \"acs-fda-sunny\"\n",
    "    CONTAINER_NAME = \"acs-fda-cosmo\"\n",
    "\n",
    "    # session id, to be provided by frontend\n",
    "    sessionId = \"326\"\n",
    "    user_id = \"guest\"\n",
    "\n",
    "    history = CosmosDBChatMessageHistory(\n",
    "        cosmos_endpoint = ENDPOINT,\n",
    "        cosmos_database = DATABASE_NAME,\n",
    "        cosmos_container = CONTAINER_NAME,\n",
    "        credential = KEY,\n",
    "        session_id = sessionId,\n",
    "        user_id = user_id,\n",
    "    )\n",
    "\n",
    "    history.prepare_cosmos()\n",
    "\n",
    "    vector_store =initialize_vector_store()\n",
    "    \n",
    "    relevant_documentation = vector_store.similarity_search(query=question, k=1, search_type=\"similarity\")\n",
    "    \n",
    "    context = \"\\n\".join([doc.page_content for doc in relevant_documentation])[:10000]\n",
    "\n",
    "    #lang = detect(question)\n",
    "\n",
    "    #print(doc)\n",
    "    #print(context)\n",
    "    #print(relevant_documentation)\n",
    "    source = relevant_documentation[0].metadata['source']\n",
    "    real_page_no = relevant_documentation[0].metadata['page']\n",
    "    website_url = relevant_documentation[0].metadata['website_url']\n",
    "\n",
    "    retriever = vector_store.as_retriever()\n",
    "\n",
    "    # add chat memory\n",
    "    memory = ConversationBufferMemory(\n",
    "        llm = llm,\n",
    "        output_key='answer',\n",
    "        memory_key='chat_history',\n",
    "        chat_memory=history,\n",
    "        return_messages=True\n",
    "    )\n",
    "\n",
    "    #QA_CHAIN_PROMPT = generate_prompt_with_history()\n",
    "\n",
    "    # The chain\n",
    "    chain = ConversationalRetrievalChain.from_llm(\n",
    "        llm,\n",
    "        retriever=retriever,\n",
    "        memory=memory,\n",
    "        combine_docs_chain_kwargs={\"prompt\": QA_CHAIN_PROMPT},\n",
    "        verbose=True,\n",
    "    )\n",
    "\n",
    "    #QA_CHAIN_PROMPT = PromptTemplate.from_template(template)\n",
    "\n",
    "    output = chain({\"question\": question})\n",
    "    \n",
    "    logging.info(output)\n",
    "    answer_value = output[\"answer\"]\n",
    "    # \n",
    "    language = \"-\"\n",
    "    \n",
    "    page_no = \"\"\n",
    "    for doc in relevant_documentation:\n",
    "        page_no = page_no + \",\" + doc.metadata['page'] \n",
    "        \n",
    "    logging.info(page_no)\n",
    "\n",
    "    if page_no == \"/\" or page_no == \"N/A\":\n",
    "        source = \"-\"\n",
    "        website_url = \"/\"\n",
    "\n",
    "    # extract first page number\n",
    "    if \",\" in page_no:\n",
    "        first_page_no  = page_no.split(\",\")[0]\n",
    "    else:\n",
    "        first_page_no = page_no\n",
    "    \n",
    "    page_no = extract_page_no(answer_value)\n",
    "    answer = extract_answer(answer_value)\n",
    "    \n",
    "    page_no = int(real_page_no) + 4\n",
    "    \n",
    "    #return answer_value\n",
    "    \n",
    "    json_response = {\n",
    "        \"raw\": output,\n",
    "        \"answer\": answer,\n",
    "        \"source\": source,\n",
    "        \"website_url\": website_url,\n",
    "        \"page_no\": page_no,\n",
    "        \"first_page_no\": first_page_no,\n",
    "        \"language\": language\n",
    "    }\n",
    "    return json_response\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mGiven the following conversation and a follow up question, rephrase the follow up question to be a standalone question, in its original language.\n",
      "\n",
      "Chat History:\n",
      "\n",
      "Human: what is Code imprint required?\n",
      "Assistant: Code imprint required refers to the regulation that mandates the marking or imprinting of a code on solid oral dosage form drug products. This code imprint, along with the product's size, shape, and color, allows for the unique identification of the drug product and its manufacturer or distributor. The code imprint must include the identification of the drug product's active ingredients and dosage strength. While the inclusion of a letter or number in the imprint is not required, it is encouraged as a more effective means of identification. Homeopathic drug products are only required to bear an imprint that identifies the manufacturer and their homeopathic nature. This requirement ensures that drug products can be easily identified and traced, promoting patient safety and regulatory compliance. [Page: 1, 2]\n",
      "Human: what is Code imprint required?\n",
      "Assistant: The purpose of the code imprint required is to ensure the unique identification of solid oral dosage form drug products and their manufacturers or distributors. By mandating the marking or imprinting of a code on these drug products, along with other identifying factors such as size, shape, and color, it becomes easier to identify and trace specific drug products. This requirement promotes patient safety by allowing for accurate identification of the drug product and its active ingredients and dosage strength. It also helps with regulatory compliance and facilitates the tracking of drug products throughout the supply chain. [Page: 1, 2]\n",
      "Human: Wholesale drug distributor licensing requirement?\n",
      "Assistant: 回答：The requirement for wholesale drug distributor licensing is that every wholesale distributor in a state who engages in wholesale distributions of prescription drugs in interstate commerce must be licensed by the state licensing authority in accordance with the regulations before engaging in wholesale distributions of prescription drugs in interstate commerce. The state licensing authority requires certain minimum information from each wholesale drug distributor, including their name, business address, telephone number, trade or business names used, addresses and contact persons for all facilities used for storage, handling, and distribution of prescription drugs, type of ownership or operation, and the names of the owner and/or operator. The state licensing authority may also provide for a single license for a business entity operating multiple facilities or for a parent entity with divisions, subsidiaries, and/or affiliate companies. Changes in the information provided must be submitted to the state licensing authority as required. [Page: 2, 3]\n",
      "Human: Wholesale drug distributor licensing requirement?\n",
      "Assistant: The state licensing authority requires the following minimum information from each wholesale drug distributor in order to obtain a license:\n",
      "\n",
      "1. The name, full business address, and telephone number of the licensee.\n",
      "2. All trade or business names used by the licensee.\n",
      "3. Addresses, telephone numbers, and the names of contact persons for all facilities used by the licensee for the storage, handling, and distribution of prescription drugs.\n",
      "4. The type of ownership or operation (i.e., partnership, corporation, or sole proprietorship).\n",
      "5. The name(s) of the owner and/or operator of the licensee, including:\n",
      "   - If a person, the name of the person.\n",
      "   - If a partnership, the name of each partner and the name of the partnership.\n",
      "   - If a corporation, the name and title of each corporate officer and director, the corporate names, and the name of the State of incorporation.\n",
      "   - If a sole proprietorship, the full name of the sole proprietor and the name of the business entity.\n",
      "\n",
      "The state licensing authority may also provide for a single license for a business entity operating multiple facilities or for a parent entity with divisions, subsidiaries, and/or affiliate companies. Any changes in the provided information must be submitted to the state licensing authority as required. [Page: 2, 3]\n",
      "Human: 如果药品中含有铁或铁盐，我该怎么办?\n",
      "Assistant: 如果药品中含有铁或铁盐，你应该按照规定进行处理。根据《21 CFR Ch. I (4–1–21 Edition) § 310.518》的规定，含有铁或铁盐作为活性成分的固体口服剂型药品（如片剂或胶囊）需要满足以下要求：\n",
      "\n",
      "1. 标签：任何含有铁或铁盐作为铁源的固体口服剂型药品的标签上必须标明以下声明：\n",
      "   - 警告：意外过量服用含铁产品是导致6岁以下儿童中毒致死的主要原因。请将此产品放在儿童无法触及的地方。如意外过量服用，请立即就医或致电中毒控制中心。\n",
      "   - 警告声明必须在即时容器标签的信息面板上显著和醒目地出现。\n",
      "   - 如果药品以单位剂量包装，并且即时容器上有标签但没有标签，警告声明必须在即时容器标签上显著和醒目地出现，以最大程度地确保警告在使用适用的所有剂量单位之前保持完好。\n",
      "   - 如果即时容器不是零售包装，警告声明还必须在零售包装标签的信息面板上显著和醒目地出现。\n",
      "   - 警告声明必须出现在包含警告的任何标签上，并通过使用细线将其放在一个方框中。\n",
      "\n",
      "2. 避免误服：为了避免儿童误服含铁产品，应将产品放在儿童无法触及的地方，并在意外过量服用时立即就医或致电中毒控制中心。\n",
      "\n",
      "根据这些规定，如果药品中含有铁或铁盐，你应该确保在药品标签上包含上述警告声明，并采取措施防止儿童误服。[Page: 1, 2]\n",
      "Human: Wholesale drug distributor licensing requirement?\n",
      "Assistant: The state licensing authority requires the following minimum information from each wholesale drug distributor in order to obtain a license:\n",
      "\n",
      "1. The name, full business address, and telephone number of the licensee.\n",
      "2. All trade or business names used by the licensee.\n",
      "3. Addresses, telephone numbers, and the names of contact persons for all facilities used by the licensee for the storage, handling, and distribution of prescription drugs.\n",
      "4. The type of ownership or operation (i.e., partnership, corporation, or sole proprietorship).\n",
      "5. The name(s) of the owner and/or operator of the licensee, including:\n",
      "   - If a person, the name of the person.\n",
      "   - If a partnership, the name of each partner and the name of the partnership.\n",
      "   - If a corporation, the name and title of each corporate officer and director, the corporate names, and the name of the State of incorporation.\n",
      "   - If a sole proprietorship, the full name of the sole proprietor and the name of the business entity.\n",
      "\n",
      "The state licensing authority may also provide for a single license for a business entity operating multiple facilities or for a parent entity with divisions, subsidiaries, and/or affiliate companies. Any changes in the provided information must be submitted to the state licensing authority as required. [Page: 2, 3]\n",
      "Human: Equipment cleanout procedures?\n",
      "Assistant: The procedures for cleaning out equipment used in the manufacture, processing, packing, or holding of a drug product are outlined in § 211.67 of the 21 CFR Ch. I (4–1–22 Edition). These procedures include the following:\n",
      "\n",
      "1. Written procedures: Written procedures should be established and followed for cleaning and maintenance of equipment, including utensils, used in the manufacturing process. These procedures should include the assignment of responsibility for cleaning and maintaining equipment.\n",
      "\n",
      "2. Maintenance and cleaning schedules: Maintenance and cleaning schedules, including sanitizing schedules where appropriate, should be established and followed.\n",
      "\n",
      "3. Description of methods, equipment, and materials: The procedures should provide a description in sufficient detail of the methods, equipment, and materials used in cleaning and maintenance operations. It should also include the methods of disassembling and reassembling equipment as necessary to ensure proper cleaning and maintenance.\n",
      "\n",
      "4. Removal or obliteration of previous batch identification: Any previous batch identification should be removed or obliterated during the cleaning process.\n",
      "\n",
      "5. Protection of clean equipment: Clean equipment should be protected from contamination prior to use.\n",
      "\n",
      "6. Inspection of equipment: Equipment should be inspected for cleanliness immediately before use.\n",
      "\n",
      "These procedures are important to prevent malfunctions or contamination that could alter the safety, identity, strength, quality, or purity of the drug product beyond the established requirements. [Page: 1, 2, 3]\n",
      "Human: Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses?\n",
      "Assistant: The process for accelerated approval of new drugs for serious or life-threatening illnesses is outlined in § 314.510 of the 21 CFR Ch. I (4–1–21 Edition). Accelerated approval allows for the expedited development, evaluation, and marketing of new therapies intended to treat persons with serious or life-threatening illnesses, especially when no satisfactory alternative therapy exists. The process involves the following steps:\n",
      "\n",
      "1. Submission of an application: The sponsor of the new drug submits an application to the Food and Drug Administration (FDA) for accelerated approval.\n",
      "\n",
      "2. Review by FDA: FDA reviews the application and determines whether the drug meets the statutory standards of safety and effectiveness. The review process may involve consultation with outside expert scientific consultants or advisory committee members.\n",
      "\n",
      "3. Agreement on study design: If the drug is intended to treat life-threatening or severely-debilitating illnesses, the sponsor may request a meeting with FDA-reviewing officials to reach an agreement on the design of necessary preclinical and clinical studies.\n",
      "\n",
      "4. Criteria for approval: FDA must determine that the patient benefit justifies the potential risks of the treatment use and that providing the investigational drug will not interfere with other clinical investigations. The drug must also meet the statutory standards for safety and effectiveness.\n",
      "\n",
      "5. Approval or tentative approval: If the drug meets the criteria for accelerated approval, FDA will issue an approval letter or a tentative approval letter. Tentative approval may be granted if there is a period of exclusivity or if additional review is required.\n",
      "\n",
      "6. Postmarketing reporting: After approval, the sponsor is responsible for postmarketing reporting of adverse drug experiences and other postmarketing reports.\n",
      "\n",
      "The accelerated approval process allows for earlier access to potentially life-saving treatments while ensuring appropriate safeguards for safety and effectiveness. [Page: 1, 2, 3, 4]\n",
      "Human: Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses?\n",
      "Assistant: The process for accelerated approval of new drugs for serious or life-threatening illnesses is outlined in § 314.510 of the 21 CFR Ch. I (4–1–21 Edition). Accelerated approval allows for the expedited development, evaluation, and marketing of new therapies intended to treat persons with serious or life-threatening illnesses, especially when no satisfactory alternative therapy exists. The process involves the following steps:\n",
      "\n",
      "1. Submission of an application: The sponsor of the new drug submits an application to the Food and Drug Administration (FDA) for accelerated approval.\n",
      "\n",
      "2. Review by FDA: FDA reviews the application and determines whether the drug meets the statutory standards of safety and effectiveness. The review process may involve consultation with outside expert scientific consultants or advisory committee members.\n",
      "\n",
      "3. Agreement on study design: If the drug is intended to treat life-threatening or severely-debilitating illnesses, the sponsor may request a meeting with FDA-reviewing officials to reach an agreement on the design of necessary preclinical and clinical studies.\n",
      "\n",
      "4. Criteria for approval: FDA must determine that the patient benefit justifies the potential risks of the treatment use and that providing the investigational drug will not interfere with other clinical investigations. The drug must also meet the statutory standards for safety and effectiveness.\n",
      "\n",
      "5. Approval or tentative approval: If the drug meets the criteria for accelerated approval, FDA will issue an approval letter or a tentative approval letter. Tentative approval may be granted if there is a period of exclusivity or if additional review is required.\n",
      "\n",
      "6. Postmarketing reporting: After approval, the sponsor is responsible for postmarketing reporting of adverse drug experiences and other postmarketing reports.\n",
      "\n",
      "The accelerated approval process allows for earlier access to potentially life-saving treatments while ensuring appropriate safeguards for safety and effectiveness. [Page: 1, 2, 3, 4]\n",
      "Human: Over-the-counter (OTC) drug products containing active ingredients offered for use in the treatment of hyperphosphatemia?\n",
      "Assistant: The requirements for over-the-counter (OTC) drug products containing active ingredients offered for use in the treatment of hyperphosphatemia are outlined in § 310.542 of the 21 CFR Ch. I (4–1–21 Edition). According to this section:\n",
      "\n",
      "1. Hyperphosphatemia is a condition in which there is an abnormally high plasma level of phosphate in the blood. It is not amenable to self-diagnosis or self-treatment, and treatment should be restricted to the supervision of a physician.\n",
      "\n",
      "2. Any drug product containing ingredients offered for OTC use in the treatment of hyperphosphatemia cannot be considered generally recognized as safe and effective.\n",
      "\n",
      "3. Any drug product labeled, represented, or promoted for OTC use in the treatment of hyperphosphatemia is regarded as a new drug and requires an approved application under section 505 of the Federal Food, Drug, and Cosmetic Act for marketing. In the absence of an approved application, such product is also misbranded.\n",
      "\n",
      "4. Clinical investigations designed to obtain evidence of the safety and effectiveness of any drug product labeled, represented, or promoted for OTC use in the treatment of hyperphosphatemia must comply with the requirements and procedures governing the use of investigational new drugs set forth in part 312 of this chapter.\n",
      "\n",
      "5. Any OTC drug product initially introduced or delivered for introduction into interstate commerce after November 12, 1990, that is not in compliance with these requirements is subject to regulatory action.\n",
      "\n",
      "[Page: 1, 2]\n",
      "Follow Up Input: Over-the-counter (OTC) drug products containing active ingredients offered for use in the treatment of hyperphosphatemia?\n",
      "Standalone question:\u001b[0m\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new StuffDocumentsChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3m\n",
      "    Follow exactly these 6 steps:\n",
      "    1. Read the context below and aggregrate this data\n",
      "    Context : 36 21 CFR Ch. I (4–1–21 Edition) § 310.542 \n",
      "(d) After November 12, 1990, any such \n",
      "OTC drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action. \n",
      "[55 FR 19858, May 11, 1990] \n",
      "§ 310.542 Over-the-counter (OTC) drug \n",
      "products containing active ingredi-ents offered for use in the treat-ment of hyperphosphatemia. \n",
      "(a) Hyperphosphatemia is a condition \n",
      "in which an abnormally high plasma level of phosphate occurs in the blood. This condition in not amenable to self- diagnosis or self-treatment. Treatment of this condition should be restricted to the supervision of a physician. For this reason, any drug product con-taining ingredients offered for OTC use in the treatment of hyperphosphatemia cannot be considered generally recog-nized as safe and effective. \n",
      "(b) Any drug product that is labeled, \n",
      "represented, or promoted for OTC use in the treatment of hyperphosphatemia is regarded as a new drug within the \n",
      "meaning of section 201(p) of the Fed-eral Food, Drug, and Cosmetic Act (the act), for which an approved application under section 505 of the act and part 314 of this chapter is required for mar-keting. In the absence of an approved application, such product is also mis-branded under section 502 of the act. \n",
      "(c) Clinical investigations designed \n",
      "to obtain evidence that any drug prod-uct labeled, represented, or promoted for use in the treatment of hyper-phosphatemia is safe and effective for the purpose intended must comply with the requirements and procedures gov-erning use of investigational new drugs set forth in part 312 of this chapter. \n",
      "(d) After November 12, 1990, any such \n",
      "OTC drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action. \n",
      "[55 FR 19858, May 11, 1990] \n",
      "§ 310.543 Drug products containing ac-\n",
      "tive ingredients offered over-the- counter (OTC) for human use in exocrine pancreatic insufficiency. \n",
      "(a) Hemicellulase, pancreatin, and \n",
      "pancrelipase have been present as in-gredients in exocrine pancreatic insuf-\n",
      "ficiency drug products. Pancreatin and pancrelipase are composed of enzymes: amylase, trypsin (protease), and lipase. Significant differences have been shown in the bioavailability of mar-keted exocrine pancreatic insufficiency drug products produced by different manufacturers. These differences raise a potential for serious risk to patients using these drug products. The bio-availability of pancreatic enzymes is dependent on the process used to man-ufacture the drug products. Informa-tion on this process is not included in an OTC drug monograph. Therefore, the safe and effective use of these en-zymes for treating exocrine pancreatic insufficiency cannot be regulated ade-quately by an OTC drug monograph. Information on the product’s formula-tion, manufacture, quality control pro-cedures, and final formulation effec-tiveness testing are necessary in an ap-proved application to ensure that a company has the ability to manufac-ture a proper bioactive formulation. In addition, continuous physician moni-toring of patients who take these drug products is a collateral measure nec-essary to the safe and effective use of these enzymes, causing such products to be available by prescription only. \n",
      "(b) Any drug product that is labeled, \n",
      "represented, or promoted for OTC use in the treatment of exocrine pancreatic insufficiency is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the act), for which an approved application under section 505 of the act and part 314 of this chapter is required for marketing. In the absence of an ap-proved application, such product is also misbranded under section 502 of the act. \n",
      "(c) Clinical investigations designed \n",
      "to obtain evidence that any drug prod-uct labeled, represented, or promoted for OTC use in the treatment of exo-crine pancreatic insufficiency is safe and effective for the purpose intended must comply with the requirements and procedures governing the use of in-vestigational new drugs set forth in part 312 of this chapter. \n",
      "VerDate Sep<11>2014 11:50 Oct 13, 2021 Jkt 253075 PO 00000 Frm 00046 Fmt 8010 Sfmt 8010 Y:\\SGML\\253075.XXX 253075spaschal on DSKJM0X7X2PROD with CFR\n",
      "\n",
      "35 Food and Drug Administration, HHS § 310.541 \n",
      "for marketing. In the absence of an ap-\n",
      "proved new drug application or abbre-viated new drug application, such prod-uct is also misbranded under section 502 of the act. \n",
      "(c) Clinical investigations designed \n",
      "to obtain evidence that any drug prod-uct labeled, represented, or promoted for OTC use for ingrown toenail relief is safe and effective for the purpose in-tended must comply with the require-ments and procedures governing the use of investigational new drugs set forth in part 312 of this chapter. \n",
      "(d) After March 9, 1994, any such OTC \n",
      "drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action. \n",
      "(e) This section does not apply to so-\n",
      "dium sulfide labeled, represented, or promoted for OTC topical use for in-grown toenail relief in accordance with part 358, subpart D of this chapter, after June 6, 2003. \n",
      "[58 FR 47605, Sept. 9, 1993, as amended at 68 \n",
      "FR 24348, May 7, 2003] \n",
      "§ 310.540 Drug products containing ac-\n",
      "tive ingredients offered over-the- \n",
      "counter (OTC) for use as stomach acidifiers. \n",
      "(a) Betaine hydrochloride, glutamic \n",
      "acid hydrochloride, diluted hydro-chloric acid, and pepsin have been present as ingredients in over-the- counter (OTC) drug products for use as stomach acidifiers. Because of the lack of adequate data to establish the effec-tiveness of these or any other ingredi-ents for use in treating achlorhydria and hypochlorhydria, and because such conditions are asymptomatic, any OTC drug product containing ingredients of-fered for use as a stomach acidifier cannot be considered generally recog-nized as safe and effective. \n",
      "(b) Any OTC drug product that is la-\n",
      "beled, represented, or promoted for use as a stomach acidifier is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act, for which an approved new drug application under section 505 of the act and part 314 of this chapter is required for marketing. In the ab-sence of an approved new drug applica-tion, such product is also misbranded \n",
      "under section 502 of the act. \n",
      "(c) Clinical investigations designed \n",
      "to obtain evidence that any drug prod-uct labeled, represented, or promoted as a stomach acidifier for OTC use is safe and effective for the purpose in-tended must comply with the require-ments and procedures governing the use of investigational new drugs set forth in part 312 of this chapter. \n",
      "(d) After the effective date of the \n",
      "final regulation, any such OTC drug product initially introduced or ini-tially delivered for introduction into interstate commerce that is not in compliance with this section is subject \n",
      "to regulatory action. \n",
      "[53 FR 31271, Aug. 17, 1988] \n",
      "§ 310.541 Over-the-counter (OTC) drug \n",
      "products containing active ingredi-ents offered for use in the treat-ment of hypophosphatemia. \n",
      "(a) Hypophosphatemia is a condition \n",
      "in which an abnormally low plasma level of phosphate occurs in the blood. This condition is not amenable to self- diagnosis or self-treatment. Treatment of this condition should be restricted to the supervision of a physician. For this reason, any drug product con-taining ingredients offered for OTC use in the treatment of hypophosphatemia cannot be considered generally recog-nized as safe and effective. \n",
      "(b) Any drug product that is labeled, \n",
      "represented, or promoted for OTC use in the treatment of hypophosphatemia is regarded as a new drug within the meaning of section 201(p) of the Fed-eral Food, Drug, and Cosmetic Act (the act), for which an approved application under section 505 of the act and part 314 of this chapter is required for mar-keting. In the absence of an approved application, such product is also mis-branded under section 502 of the act. \n",
      "(c) Clinical investigations designed \n",
      "to obtain evidence that any drug prod-uct labeled, represented, or promoted for OTC use in the treatment of hypo-phosphatemia is safe and effective for the purpose intended must comply with the requirements and procedures gov-erning the use of investigational new drugs set forth in part 312 of his chap-ter. \n",
      "VerDate Sep<11>2014 11:50 Oct 13, 2021 Jkt 253075 PO 00000 Frm 00045 Fmt 8010 Sfmt 8010 Y:\\SGML\\253075.XXX 253075spaschal on DSKJM0X7X2PROD with CFR\n",
      "\n",
      "83 Food and Drug Administration, HHS § 201.307 \n",
      "(2) Within 90 days from the date of \n",
      "publication of this statement of policy in the F\n",
      "EDERAL REGISTER , the manu-\n",
      "facturer, packer, or distributor of the drug shall submit a new-drug applica-tion containing satisfactory informa-tion of the kind required by §314.50 of this chapter, with appropriate labeling as described in this paragraph. \n",
      "(b) The Food and Drug Administra-\n",
      "tion may initiate regulatory pro-ceedings after 30 days from the date of publication of this section, with re-spect to the marketing of uncoated tablets containing potassium chloride or other potassium salts which supply 100 milligrams or more of potassium per tablet or with respect to liquid preparations containing potassium chloride or other potassium salts which supply 20 milligrams or more of potas-sium per milliliter, labeled or intended for human use, unless all the following conditions are met: \n",
      "(1) The labeling of the drug bears the \n",
      "prescription statement quoted in sec-tion 503(b)(4) of the Federal Food, Drug, and Cosmetic Act; and \n",
      "(2) The labeling on or within the \n",
      "package from which the drug is to be dispensed bears adequate information for its use by practitioners in accord with the ‘‘full disclosure’’ labeling re-quirements of §201.100 of this chapter, including a recommendation that pa-tients be directed to dissolve any such tablets in an appropriate amount of liquid and to dilute any such liquid preparations adequately to assure against gastrointestinal injury associ-ated with the oral ingestion of con-centrated potassium salt preparations. \n",
      "[40 FR 13998, Mar. 27, 1975, as amended at 55 \n",
      "FR 11576, Mar. 29, 1990; 67 FR 4906, Feb. 1, 2002] \n",
      "§ 201.307 Sodium phosphates; package \n",
      "size limitation, warnings, and direc-tions for over-the-counter sale. \n",
      "(a) Reports in the medical literature \n",
      "and data accumulated by the Food and Drug Administration indicate that multiple container sizes of sodium phosphates oral solution available in the marketplace have caused consumer confusion and appear to have been in-volved in several consumer deaths. So-dium phosphates oral solution has been marketed in 45-milliliter (mL), 90-mL, and 240-mL container sizes. The 45-mL \n",
      "and 90-mL container sizes of sodium phosphates oral solution are often rec-ommended and prescribed by physi-cians for bowel cleansing prior to sur-gery and diagnostic procedures of the colon. Sodium phosphates oral solution (adult dose 20 mL to 45 mL) is also used as an over-the-counter (OTC) laxative for the relief of occasional constipa-tion. Accidental overdosing and deaths have occurred because the 240-mL con-tainer was mistakenly used instead of the 45-mL or 90-mL container. The Food and Drug Administration is lim-iting the amount of sodium phosphates oral solution to not more than 90 mL (3 ounces (oz)) per OTC container because of the serious health risks associated with the ingestion of larger than in-tended doses of this product. Further, because an overdose of either oral or rectal enema sodium phosphates can cause an electrolyte imbalance, addi-tional warning and direction state-ments are required for the safe use of any OTC laxative drug product con-taining sodium phosphates. \n",
      "(b) Any OTC drug product for lax-\n",
      "ative or bowel cleansing use containing sodium phosphates as an active ingre-dient when marketed as described in paragraph (a) of this section is mis-branded within the meaning of section 502 of the Federal Food, Drug, and Cos-metic Act unless packaged and labeled as follows: \n",
      "(1) Package size limitation for so-\n",
      "dium phosphates oral solution: Con-tainer shall not contain more than 90 mL (3 oz). \n",
      "(2) Warnings. The following sentences \n",
      "shall appear in boldface type as the first statement under the heading ‘‘Warnings.’’ \n",
      "(i) Oral dosage forms. ‘‘Taking more \n",
      "than the recommended dose in 24 hours \n",
      "can be harmful.’’ \n",
      "(ii) Rectal enema dosage forms. \n",
      "‘‘Using more than one enema in 24 hours can be harmful.’’ \n",
      "(3) Directions—(i) The labeling of all \n",
      "orally or rectally administered OTC drug products containing sodium phosphates shall contain the following directions in boldface type imme-diately preceding the dosage informa-tion: ‘‘Do not’’ (‘‘take’’ or ‘‘use’’) \n",
      "VerDate Sep<11>2014 14:21 Nov 14, 2022 Jkt 256074 PO 00000 Frm 00093 Fmt 8010 Sfmt 8010 Y:\\SGML\\256074.XXX 256074rmajette on DSKB3F4F33PROD with CFR\n",
      "\n",
      "49 Food and Drug Administration, HHS § 201.66 \n",
      "monograph, other OTC drug regulation, \n",
      "or is included in the labeling of an ap-proved drug application. \n",
      "(i) Required information about cer-\n",
      "tain ingredients in OTC drug products (e.g., sodium in §201.64(b), calcium in §201.70(b), magnesium in §201.71(b), and potassium in §201.72(b)) shall appear as follows: ‘‘each (insert appropriate dos-age unit) contains:’’ [in bold type (in-sert name(s) of ingredient(s) (in alpha-betical order) and the quantity of each ingredient). This information shall be the first statement under this heading. \n",
      "(ii) The phenylalanine/aspartame \n",
      "content required by §201.21(b), if appli-cable, shall appear as the next item of information. \n",
      "(iii) Additional information that is \n",
      "authorized to appear under this head-ing shall appear as the next item(s) of information. There is no required order for this subsequent information. \n",
      "(8) ‘‘Inactive ingredients’’, followed \n",
      "by a listing of the established name of each inactive ingredient. If the product is an OTC drug product that is not also a cosmetic product, then the inactive ingredients shall be listed in alphabet-ical order. If the product is an OTC drug product that is also a cosmetic product, then the inactive ingredients shall be listed as set forth in §701.3(a) or (f) of this chapter, the names of cos-metic ingredients shall be determined in accordance with §701.3(c) of this chapter, and the provisions in §701.3(e), (g), (h), (l), (m), (n), and (o) of this chapter and §720.8 of this chapter may also apply, as appropriate. If there is a difference in the labeling provisions in this §201.66 and §§701.3 and 720.8 of this chapter, the labeling provisions in this §201.66 shall be used. \n",
      "(9) ‘‘Questions?’’ or ‘‘Questions or \n",
      "comments?’’, followed by the telephone number of a source to answer questions about the product. It is recommended that the days of the week and times of the day when a person is available to respond to questions also be included. A graphic of a telephone or telephone receiver may appear before the head-ing. The telephone number must ap-pear in a minimum 6-point bold type. \n",
      "(d) Format requirements. The title, \n",
      "headings, subheadings, and information set forth in paragraphs (c)(1) through (c)(9) of this section shall be presented on OTC drug products in accordance \n",
      "with the following specifications. In the interest of uniformity of presen-tation, FDA strongly reccommends that the Drug Facts labeling be pre-sented using the graphic specifications set forth in appendix A to part 201. \n",
      "(1) The title ‘‘Drug Facts’’ or ‘‘Drug \n",
      "Facts (continued)’’ shall use uppercase letters for the first letter of the words ‘‘Drug’’ and ‘‘Facts.’’ All headings and subheadings in paragraphs (c)(2) through (c)(9) of this section shall use an uppercase letter for the first letter in the first word and lowercase letters for all other words. The title, headings, and subheadings in paragraphs (c)(1), (c)(2), and (c)(4) through (c)(9) of this section shall be left justified. \n",
      "(2) The letter height or type size for \n",
      "the title ‘‘Drug Facts’’ shall appear in a type size larger than the largest type size used in the Drug Facts labeling. The letter height or type size for the title ‘‘Drug Facts (continued)’’ shall be no smaller than 8-point type. The let-ter height or type size for the headings in paragraphs (c)(2) through (c)(9) of this section shall be the larger of ei-ther 8-point or greater type, or 2-point sizes greater than the point size of the text. The letter height or type size for the subheadings and all other informa-tion described in paragraphs (c)(2) through (c)(9) of this section shall be no smaller than 6-point type. \n",
      "(3) The title, heading, subheadings, \n",
      "and information in paragraphs (c)(1) through (c)(9) of this section shall be legible and clearly presented, shall have at least 0.5-point leading (i.e., space between two lines of text), and shall not have letters that touch. The type style for the title, headings, sub-headings, and all other required infor-mation described in paragraphs (c)(2) through (c)(9) of this section shall be any single, clear, easy-to-read type style, with no more than 39 characters per inch. The title and headings shall be in bold italic, and the subheadings shall be in bold type, except that the word ‘‘(continued)’’ in the title ‘‘Drug Facts (continued)’’ shall be regular \n",
      "type. The type shall be all black or one color printed on a white or other con-trasting background, except that the \n",
      "VerDate Sep<11>2014 14:21 Nov 14, 2022 Jkt 256074 PO 00000 Frm 00059 Fmt 8010 Sfmt 8010 Y:\\SGML\\256074.XXX 256074rmajette on DSKB3F4F33PROD with CFR\n",
      "    2. Answer the question using only this context and the chat history below\n",
      "    3. Answer the question in less than 200 words\n",
      "    4. Please provide the page number of the pages where your answer are based on at the end of your response\n",
      "    5. Please provide the page numbers in the following output format: [Page: 1, 2, 3...]\n",
      "    6. Allow the chat continue by following Chat History\n",
      "    \n",
      "    Chat History: \n",
      "Human: what is Code imprint required?\n",
      "Assistant: Code imprint required refers to the regulation that mandates the marking or imprinting of a code on solid oral dosage form drug products. This code imprint, along with the product's size, shape, and color, allows for the unique identification of the drug product and its manufacturer or distributor. The code imprint must include the identification of the drug product's active ingredients and dosage strength. While the inclusion of a letter or number in the imprint is not required, it is encouraged as a more effective means of identification. Homeopathic drug products are only required to bear an imprint that identifies the manufacturer and their homeopathic nature. This requirement ensures that drug products can be easily identified and traced, promoting patient safety and regulatory compliance. [Page: 1, 2]\n",
      "Human: what is Code imprint required?\n",
      "Assistant: The purpose of the code imprint required is to ensure the unique identification of solid oral dosage form drug products and their manufacturers or distributors. By mandating the marking or imprinting of a code on these drug products, along with other identifying factors such as size, shape, and color, it becomes easier to identify and trace specific drug products. This requirement promotes patient safety by allowing for accurate identification of the drug product and its active ingredients and dosage strength. It also helps with regulatory compliance and facilitates the tracking of drug products throughout the supply chain. [Page: 1, 2]\n",
      "Human: Wholesale drug distributor licensing requirement?\n",
      "Assistant: 回答：The requirement for wholesale drug distributor licensing is that every wholesale distributor in a state who engages in wholesale distributions of prescription drugs in interstate commerce must be licensed by the state licensing authority in accordance with the regulations before engaging in wholesale distributions of prescription drugs in interstate commerce. The state licensing authority requires certain minimum information from each wholesale drug distributor, including their name, business address, telephone number, trade or business names used, addresses and contact persons for all facilities used for storage, handling, and distribution of prescription drugs, type of ownership or operation, and the names of the owner and/or operator. The state licensing authority may also provide for a single license for a business entity operating multiple facilities or for a parent entity with divisions, subsidiaries, and/or affiliate companies. Changes in the information provided must be submitted to the state licensing authority as required. [Page: 2, 3]\n",
      "Human: Wholesale drug distributor licensing requirement?\n",
      "Assistant: The state licensing authority requires the following minimum information from each wholesale drug distributor in order to obtain a license:\n",
      "\n",
      "1. The name, full business address, and telephone number of the licensee.\n",
      "2. All trade or business names used by the licensee.\n",
      "3. Addresses, telephone numbers, and the names of contact persons for all facilities used by the licensee for the storage, handling, and distribution of prescription drugs.\n",
      "4. The type of ownership or operation (i.e., partnership, corporation, or sole proprietorship).\n",
      "5. The name(s) of the owner and/or operator of the licensee, including:\n",
      "   - If a person, the name of the person.\n",
      "   - If a partnership, the name of each partner and the name of the partnership.\n",
      "   - If a corporation, the name and title of each corporate officer and director, the corporate names, and the name of the State of incorporation.\n",
      "   - If a sole proprietorship, the full name of the sole proprietor and the name of the business entity.\n",
      "\n",
      "The state licensing authority may also provide for a single license for a business entity operating multiple facilities or for a parent entity with divisions, subsidiaries, and/or affiliate companies. Any changes in the provided information must be submitted to the state licensing authority as required. [Page: 2, 3]\n",
      "Human: 如果药品中含有铁或铁盐，我该怎么办?\n",
      "Assistant: 如果药品中含有铁或铁盐，你应该按照规定进行处理。根据《21 CFR Ch. I (4–1–21 Edition) § 310.518》的规定，含有铁或铁盐作为活性成分的固体口服剂型药品（如片剂或胶囊）需要满足以下要求：\n",
      "\n",
      "1. 标签：任何含有铁或铁盐作为铁源的固体口服剂型药品的标签上必须标明以下声明：\n",
      "   - 警告：意外过量服用含铁产品是导致6岁以下儿童中毒致死的主要原因。请将此产品放在儿童无法触及的地方。如意外过量服用，请立即就医或致电中毒控制中心。\n",
      "   - 警告声明必须在即时容器标签的信息面板上显著和醒目地出现。\n",
      "   - 如果药品以单位剂量包装，并且即时容器上有标签但没有标签，警告声明必须在即时容器标签上显著和醒目地出现，以最大程度地确保警告在使用适用的所有剂量单位之前保持完好。\n",
      "   - 如果即时容器不是零售包装，警告声明还必须在零售包装标签的信息面板上显著和醒目地出现。\n",
      "   - 警告声明必须出现在包含警告的任何标签上，并通过使用细线将其放在一个方框中。\n",
      "\n",
      "2. 避免误服：为了避免儿童误服含铁产品，应将产品放在儿童无法触及的地方，并在意外过量服用时立即就医或致电中毒控制中心。\n",
      "\n",
      "根据这些规定，如果药品中含有铁或铁盐，你应该确保在药品标签上包含上述警告声明，并采取措施防止儿童误服。[Page: 1, 2]\n",
      "Human: Wholesale drug distributor licensing requirement?\n",
      "Assistant: The state licensing authority requires the following minimum information from each wholesale drug distributor in order to obtain a license:\n",
      "\n",
      "1. The name, full business address, and telephone number of the licensee.\n",
      "2. All trade or business names used by the licensee.\n",
      "3. Addresses, telephone numbers, and the names of contact persons for all facilities used by the licensee for the storage, handling, and distribution of prescription drugs.\n",
      "4. The type of ownership or operation (i.e., partnership, corporation, or sole proprietorship).\n",
      "5. The name(s) of the owner and/or operator of the licensee, including:\n",
      "   - If a person, the name of the person.\n",
      "   - If a partnership, the name of each partner and the name of the partnership.\n",
      "   - If a corporation, the name and title of each corporate officer and director, the corporate names, and the name of the State of incorporation.\n",
      "   - If a sole proprietorship, the full name of the sole proprietor and the name of the business entity.\n",
      "\n",
      "The state licensing authority may also provide for a single license for a business entity operating multiple facilities or for a parent entity with divisions, subsidiaries, and/or affiliate companies. Any changes in the provided information must be submitted to the state licensing authority as required. [Page: 2, 3]\n",
      "Human: Equipment cleanout procedures?\n",
      "Assistant: The procedures for cleaning out equipment used in the manufacture, processing, packing, or holding of a drug product are outlined in § 211.67 of the 21 CFR Ch. I (4–1–22 Edition). These procedures include the following:\n",
      "\n",
      "1. Written procedures: Written procedures should be established and followed for cleaning and maintenance of equipment, including utensils, used in the manufacturing process. These procedures should include the assignment of responsibility for cleaning and maintaining equipment.\n",
      "\n",
      "2. Maintenance and cleaning schedules: Maintenance and cleaning schedules, including sanitizing schedules where appropriate, should be established and followed.\n",
      "\n",
      "3. Description of methods, equipment, and materials: The procedures should provide a description in sufficient detail of the methods, equipment, and materials used in cleaning and maintenance operations. It should also include the methods of disassembling and reassembling equipment as necessary to ensure proper cleaning and maintenance.\n",
      "\n",
      "4. Removal or obliteration of previous batch identification: Any previous batch identification should be removed or obliterated during the cleaning process.\n",
      "\n",
      "5. Protection of clean equipment: Clean equipment should be protected from contamination prior to use.\n",
      "\n",
      "6. Inspection of equipment: Equipment should be inspected for cleanliness immediately before use.\n",
      "\n",
      "These procedures are important to prevent malfunctions or contamination that could alter the safety, identity, strength, quality, or purity of the drug product beyond the established requirements. [Page: 1, 2, 3]\n",
      "Human: Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses?\n",
      "Assistant: The process for accelerated approval of new drugs for serious or life-threatening illnesses is outlined in § 314.510 of the 21 CFR Ch. I (4–1–21 Edition). Accelerated approval allows for the expedited development, evaluation, and marketing of new therapies intended to treat persons with serious or life-threatening illnesses, especially when no satisfactory alternative therapy exists. The process involves the following steps:\n",
      "\n",
      "1. Submission of an application: The sponsor of the new drug submits an application to the Food and Drug Administration (FDA) for accelerated approval.\n",
      "\n",
      "2. Review by FDA: FDA reviews the application and determines whether the drug meets the statutory standards of safety and effectiveness. The review process may involve consultation with outside expert scientific consultants or advisory committee members.\n",
      "\n",
      "3. Agreement on study design: If the drug is intended to treat life-threatening or severely-debilitating illnesses, the sponsor may request a meeting with FDA-reviewing officials to reach an agreement on the design of necessary preclinical and clinical studies.\n",
      "\n",
      "4. Criteria for approval: FDA must determine that the patient benefit justifies the potential risks of the treatment use and that providing the investigational drug will not interfere with other clinical investigations. The drug must also meet the statutory standards for safety and effectiveness.\n",
      "\n",
      "5. Approval or tentative approval: If the drug meets the criteria for accelerated approval, FDA will issue an approval letter or a tentative approval letter. Tentative approval may be granted if there is a period of exclusivity or if additional review is required.\n",
      "\n",
      "6. Postmarketing reporting: After approval, the sponsor is responsible for postmarketing reporting of adverse drug experiences and other postmarketing reports.\n",
      "\n",
      "The accelerated approval process allows for earlier access to potentially life-saving treatments while ensuring appropriate safeguards for safety and effectiveness. [Page: 1, 2, 3, 4]\n",
      "Human: Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses?\n",
      "Assistant: The process for accelerated approval of new drugs for serious or life-threatening illnesses is outlined in § 314.510 of the 21 CFR Ch. I (4–1–21 Edition). Accelerated approval allows for the expedited development, evaluation, and marketing of new therapies intended to treat persons with serious or life-threatening illnesses, especially when no satisfactory alternative therapy exists. The process involves the following steps:\n",
      "\n",
      "1. Submission of an application: The sponsor of the new drug submits an application to the Food and Drug Administration (FDA) for accelerated approval.\n",
      "\n",
      "2. Review by FDA: FDA reviews the application and determines whether the drug meets the statutory standards of safety and effectiveness. The review process may involve consultation with outside expert scientific consultants or advisory committee members.\n",
      "\n",
      "3. Agreement on study design: If the drug is intended to treat life-threatening or severely-debilitating illnesses, the sponsor may request a meeting with FDA-reviewing officials to reach an agreement on the design of necessary preclinical and clinical studies.\n",
      "\n",
      "4. Criteria for approval: FDA must determine that the patient benefit justifies the potential risks of the treatment use and that providing the investigational drug will not interfere with other clinical investigations. The drug must also meet the statutory standards for safety and effectiveness.\n",
      "\n",
      "5. Approval or tentative approval: If the drug meets the criteria for accelerated approval, FDA will issue an approval letter or a tentative approval letter. Tentative approval may be granted if there is a period of exclusivity or if additional review is required.\n",
      "\n",
      "6. Postmarketing reporting: After approval, the sponsor is responsible for postmarketing reporting of adverse drug experiences and other postmarketing reports.\n",
      "\n",
      "The accelerated approval process allows for earlier access to potentially life-saving treatments while ensuring appropriate safeguards for safety and effectiveness. [Page: 1, 2, 3, 4]\n",
      "Human: Over-the-counter (OTC) drug products containing active ingredients offered for use in the treatment of hyperphosphatemia?\n",
      "Assistant: The requirements for over-the-counter (OTC) drug products containing active ingredients offered for use in the treatment of hyperphosphatemia are outlined in § 310.542 of the 21 CFR Ch. I (4–1–21 Edition). According to this section:\n",
      "\n",
      "1. Hyperphosphatemia is a condition in which there is an abnormally high plasma level of phosphate in the blood. It is not amenable to self-diagnosis or self-treatment, and treatment should be restricted to the supervision of a physician.\n",
      "\n",
      "2. Any drug product containing ingredients offered for OTC use in the treatment of hyperphosphatemia cannot be considered generally recognized as safe and effective.\n",
      "\n",
      "3. Any drug product labeled, represented, or promoted for OTC use in the treatment of hyperphosphatemia is regarded as a new drug and requires an approved application under section 505 of the Federal Food, Drug, and Cosmetic Act for marketing. In the absence of an approved application, such product is also misbranded.\n",
      "\n",
      "4. Clinical investigations designed to obtain evidence of the safety and effectiveness of any drug product labeled, represented, or promoted for OTC use in the treatment of hyperphosphatemia must comply with the requirements and procedures governing the use of investigational new drugs set forth in part 312 of this chapter.\n",
      "\n",
      "5. Any OTC drug product initially introduced or delivered for introduction into interstate commerce after November 12, 1990, that is not in compliance with these requirements is subject to regulatory action.\n",
      "\n",
      "[Page: 1, 2]\n",
      "\n",
      "    User Question: What are the requirements for over-the-counter (OTC) drug products containing active ingredients offered for use in the treatment of hyperphosphatemia?\n",
      "\n",
      "\n",
      "    If you don't have any context and are unsure of the answer, reply that you don't know about this topic.\n",
      "    \u001b[0m\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      " 1, 2]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'raw': {'question': 'Over-the-counter (OTC) drug products containing active ingredients offered for use in the treatment of hyperphosphatemia?',\n",
       "  'chat_history': [HumanMessage(content='what is Code imprint required?', additional_kwargs={}, example=False),\n",
       "   AIMessage(content=\"Code imprint required refers to the regulation that mandates the marking or imprinting of a code on solid oral dosage form drug products. This code imprint, along with the product's size, shape, and color, allows for the unique identification of the drug product and its manufacturer or distributor. The code imprint must include the identification of the drug product's active ingredients and dosage strength. While the inclusion of a letter or number in the imprint is not required, it is encouraged as a more effective means of identification. Homeopathic drug products are only required to bear an imprint that identifies the manufacturer and their homeopathic nature. This requirement ensures that drug products can be easily identified and traced, promoting patient safety and regulatory compliance. [Page: 1, 2]\", additional_kwargs={}, example=False),\n",
       "   HumanMessage(content='what is Code imprint required?', additional_kwargs={}, example=False),\n",
       "   AIMessage(content='The purpose of the code imprint required is to ensure the unique identification of solid oral dosage form drug products and their manufacturers or distributors. By mandating the marking or imprinting of a code on these drug products, along with other identifying factors such as size, shape, and color, it becomes easier to identify and trace specific drug products. This requirement promotes patient safety by allowing for accurate identification of the drug product and its active ingredients and dosage strength. It also helps with regulatory compliance and facilitates the tracking of drug products throughout the supply chain. [Page: 1, 2]', additional_kwargs={}, example=False),\n",
       "   HumanMessage(content='Wholesale drug distributor licensing requirement?', additional_kwargs={}, example=False),\n",
       "   AIMessage(content='回答：The requirement for wholesale drug distributor licensing is that every wholesale distributor in a state who engages in wholesale distributions of prescription drugs in interstate commerce must be licensed by the state licensing authority in accordance with the regulations before engaging in wholesale distributions of prescription drugs in interstate commerce. The state licensing authority requires certain minimum information from each wholesale drug distributor, including their name, business address, telephone number, trade or business names used, addresses and contact persons for all facilities used for storage, handling, and distribution of prescription drugs, type of ownership or operation, and the names of the owner and/or operator. The state licensing authority may also provide for a single license for a business entity operating multiple facilities or for a parent entity with divisions, subsidiaries, and/or affiliate companies. Changes in the information provided must be submitted to the state licensing authority as required. [Page: 2, 3]', additional_kwargs={}, example=False),\n",
       "   HumanMessage(content='Wholesale drug distributor licensing requirement?', additional_kwargs={}, example=False),\n",
       "   AIMessage(content='The state licensing authority requires the following minimum information from each wholesale drug distributor in order to obtain a license:\\n\\n1. The name, full business address, and telephone number of the licensee.\\n2. All trade or business names used by the licensee.\\n3. Addresses, telephone numbers, and the names of contact persons for all facilities used by the licensee for the storage, handling, and distribution of prescription drugs.\\n4. The type of ownership or operation (i.e., partnership, corporation, or sole proprietorship).\\n5. The name(s) of the owner and/or operator of the licensee, including:\\n   - If a person, the name of the person.\\n   - If a partnership, the name of each partner and the name of the partnership.\\n   - If a corporation, the name and title of each corporate officer and director, the corporate names, and the name of the State of incorporation.\\n   - If a sole proprietorship, the full name of the sole proprietor and the name of the business entity.\\n\\nThe state licensing authority may also provide for a single license for a business entity operating multiple facilities or for a parent entity with divisions, subsidiaries, and/or affiliate companies. Any changes in the provided information must be submitted to the state licensing authority as required. [Page: 2, 3]', additional_kwargs={}, example=False),\n",
       "   HumanMessage(content='如果药品中含有铁或铁盐，我该怎么办?', additional_kwargs={}, example=False),\n",
       "   AIMessage(content='如果药品中含有铁或铁盐，你应该按照规定进行处理。根据《21 CFR Ch. I (4–1–21 Edition) § 310.518》的规定，含有铁或铁盐作为活性成分的固体口服剂型药品（如片剂或胶囊）需要满足以下要求：\\n\\n1. 标签：任何含有铁或铁盐作为铁源的固体口服剂型药品的标签上必须标明以下声明：\\n   - 警告：意外过量服用含铁产品是导致6岁以下儿童中毒致死的主要原因。请将此产品放在儿童无法触及的地方。如意外过量服用，请立即就医或致电中毒控制中心。\\n   - 警告声明必须在即时容器标签的信息面板上显著和醒目地出现。\\n   - 如果药品以单位剂量包装，并且即时容器上有标签但没有标签，警告声明必须在即时容器标签上显著和醒目地出现，以最大程度地确保警告在使用适用的所有剂量单位之前保持完好。\\n   - 如果即时容器不是零售包装，警告声明还必须在零售包装标签的信息面板上显著和醒目地出现。\\n   - 警告声明必须出现在包含警告的任何标签上，并通过使用细线将其放在一个方框中。\\n\\n2. 避免误服：为了避免儿童误服含铁产品，应将产品放在儿童无法触及的地方，并在意外过量服用时立即就医或致电中毒控制中心。\\n\\n根据这些规定，如果药品中含有铁或铁盐，你应该确保在药品标签上包含上述警告声明，并采取措施防止儿童误服。[Page: 1, 2]', additional_kwargs={}, example=False),\n",
       "   HumanMessage(content='Wholesale drug distributor licensing requirement?', additional_kwargs={}, example=False),\n",
       "   AIMessage(content='The state licensing authority requires the following minimum information from each wholesale drug distributor in order to obtain a license:\\n\\n1. The name, full business address, and telephone number of the licensee.\\n2. All trade or business names used by the licensee.\\n3. Addresses, telephone numbers, and the names of contact persons for all facilities used by the licensee for the storage, handling, and distribution of prescription drugs.\\n4. The type of ownership or operation (i.e., partnership, corporation, or sole proprietorship).\\n5. The name(s) of the owner and/or operator of the licensee, including:\\n   - If a person, the name of the person.\\n   - If a partnership, the name of each partner and the name of the partnership.\\n   - If a corporation, the name and title of each corporate officer and director, the corporate names, and the name of the State of incorporation.\\n   - If a sole proprietorship, the full name of the sole proprietor and the name of the business entity.\\n\\nThe state licensing authority may also provide for a single license for a business entity operating multiple facilities or for a parent entity with divisions, subsidiaries, and/or affiliate companies. Any changes in the provided information must be submitted to the state licensing authority as required. [Page: 2, 3]', additional_kwargs={}, example=False),\n",
       "   HumanMessage(content='Equipment cleanout procedures?', additional_kwargs={}, example=False),\n",
       "   AIMessage(content='The procedures for cleaning out equipment used in the manufacture, processing, packing, or holding of a drug product are outlined in § 211.67 of the 21 CFR Ch. I (4–1–22 Edition). These procedures include the following:\\n\\n1. Written procedures: Written procedures should be established and followed for cleaning and maintenance of equipment, including utensils, used in the manufacturing process. These procedures should include the assignment of responsibility for cleaning and maintaining equipment.\\n\\n2. Maintenance and cleaning schedules: Maintenance and cleaning schedules, including sanitizing schedules where appropriate, should be established and followed.\\n\\n3. Description of methods, equipment, and materials: The procedures should provide a description in sufficient detail of the methods, equipment, and materials used in cleaning and maintenance operations. It should also include the methods of disassembling and reassembling equipment as necessary to ensure proper cleaning and maintenance.\\n\\n4. Removal or obliteration of previous batch identification: Any previous batch identification should be removed or obliterated during the cleaning process.\\n\\n5. Protection of clean equipment: Clean equipment should be protected from contamination prior to use.\\n\\n6. Inspection of equipment: Equipment should be inspected for cleanliness immediately before use.\\n\\nThese procedures are important to prevent malfunctions or contamination that could alter the safety, identity, strength, quality, or purity of the drug product beyond the established requirements. [Page: 1, 2, 3]', additional_kwargs={}, example=False),\n",
       "   HumanMessage(content='Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses?', additional_kwargs={}, example=False),\n",
       "   AIMessage(content='The process for accelerated approval of new drugs for serious or life-threatening illnesses is outlined in § 314.510 of the 21 CFR Ch. I (4–1–21 Edition). Accelerated approval allows for the expedited development, evaluation, and marketing of new therapies intended to treat persons with serious or life-threatening illnesses, especially when no satisfactory alternative therapy exists. The process involves the following steps:\\n\\n1. Submission of an application: The sponsor of the new drug submits an application to the Food and Drug Administration (FDA) for accelerated approval.\\n\\n2. Review by FDA: FDA reviews the application and determines whether the drug meets the statutory standards of safety and effectiveness. The review process may involve consultation with outside expert scientific consultants or advisory committee members.\\n\\n3. Agreement on study design: If the drug is intended to treat life-threatening or severely-debilitating illnesses, the sponsor may request a meeting with FDA-reviewing officials to reach an agreement on the design of necessary preclinical and clinical studies.\\n\\n4. Criteria for approval: FDA must determine that the patient benefit justifies the potential risks of the treatment use and that providing the investigational drug will not interfere with other clinical investigations. The drug must also meet the statutory standards for safety and effectiveness.\\n\\n5. Approval or tentative approval: If the drug meets the criteria for accelerated approval, FDA will issue an approval letter or a tentative approval letter. Tentative approval may be granted if there is a period of exclusivity or if additional review is required.\\n\\n6. Postmarketing reporting: After approval, the sponsor is responsible for postmarketing reporting of adverse drug experiences and other postmarketing reports.\\n\\nThe accelerated approval process allows for earlier access to potentially life-saving treatments while ensuring appropriate safeguards for safety and effectiveness. [Page: 1, 2, 3, 4]', additional_kwargs={}, example=False),\n",
       "   HumanMessage(content='Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses?', additional_kwargs={}, example=False),\n",
       "   AIMessage(content='The process for accelerated approval of new drugs for serious or life-threatening illnesses is outlined in § 314.510 of the 21 CFR Ch. I (4–1–21 Edition). Accelerated approval allows for the expedited development, evaluation, and marketing of new therapies intended to treat persons with serious or life-threatening illnesses, especially when no satisfactory alternative therapy exists. The process involves the following steps:\\n\\n1. Submission of an application: The sponsor of the new drug submits an application to the Food and Drug Administration (FDA) for accelerated approval.\\n\\n2. Review by FDA: FDA reviews the application and determines whether the drug meets the statutory standards of safety and effectiveness. The review process may involve consultation with outside expert scientific consultants or advisory committee members.\\n\\n3. Agreement on study design: If the drug is intended to treat life-threatening or severely-debilitating illnesses, the sponsor may request a meeting with FDA-reviewing officials to reach an agreement on the design of necessary preclinical and clinical studies.\\n\\n4. Criteria for approval: FDA must determine that the patient benefit justifies the potential risks of the treatment use and that providing the investigational drug will not interfere with other clinical investigations. The drug must also meet the statutory standards for safety and effectiveness.\\n\\n5. Approval or tentative approval: If the drug meets the criteria for accelerated approval, FDA will issue an approval letter or a tentative approval letter. Tentative approval may be granted if there is a period of exclusivity or if additional review is required.\\n\\n6. Postmarketing reporting: After approval, the sponsor is responsible for postmarketing reporting of adverse drug experiences and other postmarketing reports.\\n\\nThe accelerated approval process allows for earlier access to potentially life-saving treatments while ensuring appropriate safeguards for safety and effectiveness. [Page: 1, 2, 3, 4]', additional_kwargs={}, example=False),\n",
       "   HumanMessage(content='Over-the-counter (OTC) drug products containing active ingredients offered for use in the treatment of hyperphosphatemia?', additional_kwargs={}, example=False),\n",
       "   AIMessage(content='The requirements for over-the-counter (OTC) drug products containing active ingredients offered for use in the treatment of hyperphosphatemia are outlined in § 310.542 of the 21 CFR Ch. I (4–1–21 Edition). According to this section:\\n\\n1. Hyperphosphatemia is a condition in which there is an abnormally high plasma level of phosphate in the blood. It is not amenable to self-diagnosis or self-treatment, and treatment should be restricted to the supervision of a physician.\\n\\n2. Any drug product containing ingredients offered for OTC use in the treatment of hyperphosphatemia cannot be considered generally recognized as safe and effective.\\n\\n3. Any drug product labeled, represented, or promoted for OTC use in the treatment of hyperphosphatemia is regarded as a new drug and requires an approved application under section 505 of the Federal Food, Drug, and Cosmetic Act for marketing. In the absence of an approved application, such product is also misbranded.\\n\\n4. Clinical investigations designed to obtain evidence of the safety and effectiveness of any drug product labeled, represented, or promoted for OTC use in the treatment of hyperphosphatemia must comply with the requirements and procedures governing the use of investigational new drugs set forth in part 312 of this chapter.\\n\\n5. Any OTC drug product initially introduced or delivered for introduction into interstate commerce after November 12, 1990, that is not in compliance with these requirements is subject to regulatory action.\\n\\n[Page: 1, 2]', additional_kwargs={}, example=False),\n",
       "   HumanMessage(content='Over-the-counter (OTC) drug products containing active ingredients offered for use in the treatment of hyperphosphatemia?', additional_kwargs={}, example=False),\n",
       "   AIMessage(content='The requirements for over-the-counter (OTC) drug products containing active ingredients offered for use in the treatment of hyperphosphatemia are outlined in § 310.542 of the 21 CFR Ch. I (4–1–21 Edition). According to this section:\\n\\n1. Hyperphosphatemia is a condition in which there is an abnormally high plasma level of phosphate in the blood. It is not amenable to self-diagnosis or self-treatment, and treatment should be restricted to the supervision of a physician.\\n\\n2. Any drug product containing ingredients offered for OTC use in the treatment of hyperphosphatemia cannot be considered generally recognized as safe and effective.\\n\\n3. Any drug product labeled, represented, or promoted for OTC use in the treatment of hyperphosphatemia is regarded as a new drug and requires an approved application under section 505 of the Federal Food, Drug, and Cosmetic Act for marketing. In the absence of an approved application, such product is also misbranded.\\n\\n4. Clinical investigations designed to obtain evidence of the safety and effectiveness of any drug product labeled, represented, or promoted for OTC use in the treatment of hyperphosphatemia must comply with the requirements and procedures governing the use of investigational new drugs set forth in part 312 of this chapter.\\n\\n5. Any OTC drug product initially introduced or delivered for introduction into interstate commerce after November 12, 1990, that is not in compliance with these requirements is subject to regulatory action.\\n\\n[Page: 1, 2]', additional_kwargs={}, example=False)],\n",
       "  'answer': 'The requirements for over-the-counter (OTC) drug products containing active ingredients offered for use in the treatment of hyperphosphatemia are outlined in § 310.542 of the 21 CFR Ch. I (4–1–21 Edition). According to this section:\\n\\n1. Hyperphosphatemia is a condition in which there is an abnormally high plasma level of phosphate in the blood. It is not amenable to self-diagnosis or self-treatment, and treatment should be restricted to the supervision of a physician.\\n\\n2. Any drug product containing ingredients offered for OTC use in the treatment of hyperphosphatemia cannot be considered generally recognized as safe and effective.\\n\\n3. Any drug product labeled, represented, or promoted for OTC use in the treatment of hyperphosphatemia is regarded as a new drug and requires an approved application under section 505 of the Federal Food, Drug, and Cosmetic Act for marketing. In the absence of an approved application, such product is also misbranded.\\n\\n4. Clinical investigations designed to obtain evidence of the safety and effectiveness of any drug product labeled, represented, or promoted for OTC use in the treatment of hyperphosphatemia must comply with the requirements and procedures governing the use of investigational new drugs set forth in part 312 of this chapter.\\n\\n5. Any OTC drug product initially introduced or delivered for introduction into interstate commerce after November 12, 1990, that is not in compliance with these requirements is subject to regulatory action.\\n\\n[Page: 1, 2]'},\n",
       " 'answer': 'The requirements for over-the-counter (OTC) drug products containing active ingredients offered for use in the treatment of hyperphosphatemia are outlined in § 310.542 of the 21 CFR Ch. I (4–1–21 Edition). According to this section:\\n\\n1. Hyperphosphatemia is a condition in which there is an abnormally high plasma level of phosphate in the blood. It is not amenable to self-diagnosis or self-treatment, and treatment should be restricted to the supervision of a physician.\\n\\n2. Any drug product containing ingredients offered for OTC use in the treatment of hyperphosphatemia cannot be considered generally recognized as safe and effective.\\n\\n3. Any drug product labeled, represented, or promoted for OTC use in the treatment of hyperphosphatemia is regarded as a new drug and requires an approved application under section 505 of the Federal Food, Drug, and Cosmetic Act for marketing. In the absence of an approved application, such product is also misbranded.\\n\\n4. Clinical investigations designed to obtain evidence of the safety and effectiveness of any drug product labeled, represented, or promoted for OTC use in the treatment of hyperphosphatemia must comply with the requirements and procedures governing the use of investigational new drugs set forth in part 312 of this chapter.\\n\\n5. Any OTC drug product initially introduced or delivered for introduction into interstate commerce after November 12, 1990, that is not in compliance with these requirements is subject to regulatory action.\\n\\n',\n",
       " 'source': 'CFR-2022-title21-vol5-chapI-subchapD.pdf',\n",
       " 'website_url': '/',\n",
       " 'page_no': 36,\n",
       " 'first_page_no': '',\n",
       " 'language': '-'}"
      ]
     },
     "execution_count": 63,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "question = \"Over-the-counter (OTC) drug products containing active ingredients offered for use in the treatment of hyperphosphatemia?\"\n",
    "\n",
    "llm_pipeline_with_history(question)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'history' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[31], line 11\u001b[0m\n\u001b[0;32m      7\u001b[0m             \u001b[38;5;28mprint\u001b[39m(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mAI: \u001b[39m\u001b[38;5;124m\"\u001b[39m \u001b[38;5;241m+\u001b[39m message\u001b[38;5;241m.\u001b[39mcontent)\n\u001b[0;32m      8\u001b[0m         i\u001b[38;5;241m+\u001b[39m\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m1\u001b[39m\n\u001b[1;32m---> 11\u001b[0m retrieve_chat_history(history)\n",
      "\u001b[1;31mNameError\u001b[0m: name 'history' is not defined"
     ]
    }
   ],
   "source": [
    "def retrieve_chat_history(history):\n",
    "    i = 0\n",
    "    for message in history.messages:\n",
    "        if i % 2 == 0:\n",
    "            print(\"Human: \" + message.content)\n",
    "        else:\n",
    "            print(\"AI: \" + message.content)\n",
    "        i+=1\n",
    "\n",
    "\n",
    "retrieve_chat_history(history)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "%pip show langchain"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "%pip show azure-search-documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# do not run, not use this for memory\n",
    "\n",
    "def llm_pipeline(question):\n",
    "    # set up index name \n",
    "    index_name = os.environ[\"AZURE_INDEX_NAME\"] \n",
    "\n",
    "    # retrieve information from Azure Search\n",
    "    relevant_docs, source, website_url, language, page_no = azure_search_by_index(question, index_name)\n",
    "\n",
    "    #print(relevant_docs)\n",
    "\n",
    "    # generate prompt without example\n",
    "\n",
    "    if language == \"en\":\n",
    "    #english prompt\n",
    "        PROMPT = generate_prompt()\n",
    "    else:\n",
    "        PROMPT = generate_prompt_chi()\n",
    "\n",
    "    os.environ[\"OPENAI_API_TYPE\"] = \"azure\"\n",
    "    os.environ[\"OPENAI_API_VERSION\"] = \"2023-05-15\"\n",
    "    os.environ[\"OPENAI_API_BASE\"] = \"https://pwcjay.openai.azure.com/\"\n",
    "    os.environ[\"OPENAI_API_KEY\"] = \"f282a661571f45a0bdfdcd295ac808e7\"\n",
    "\n",
    "\n",
    "    # use AzureChatOpenAI \n",
    "    llm = AzureChatOpenAI(deployment_name=\"gpt-35-16k\", temperature=0,\n",
    "                        openai_api_version=\"2023-05-15\", openai_api_base=\"https://pwcjay.openai.azure.com/\")\n",
    "\n",
    "\n",
    "    # set up chat history database credentials\n",
    "    os.environ[\"COSMOS_ENDPOINT\"] = \"https://gpt-demo-chat-history.documents.azure.com:443/\"\n",
    "    os.environ[\"COSMOS_KEY\"] = \"AZEhMpW4YD3t7iEMgp9at48S7f5ZjvnahUqJMYjMjMpH2QH2wiYBL97RdX7AqL3CMQcGGhbdAFHvACDbDDwMyA==\"\n",
    "    ENDPOINT = os.environ[\"COSMOS_ENDPOINT\"]\n",
    "    KEY = os.environ[\"COSMOS_KEY\"]\n",
    "    DATABASE_NAME = \"sino_demo\"\n",
    "    CONTAINER_NAME = \"sino_chat_history\"\n",
    "    sessionId = \"101\"\n",
    "    user_id = \"Sunny\"\n",
    "\n",
    "    history = CosmosDBChatMessageHistory(\n",
    "        cosmos_endpoint = ENDPOINT,\n",
    "        cosmos_database = DATABASE_NAME,\n",
    "        cosmos_container = CONTAINER_NAME,\n",
    "        credential = KEY,\n",
    "        session_id = sessionId,\n",
    "        user_id = user_id,\n",
    "    )\n",
    "\n",
    "    history.prepare_cosmos()\n",
    "\n",
    "\n",
    "\n",
    "    # add chat memory\n",
    "    memory = ConversationBufferMemory(\n",
    "        llm = llm,\n",
    "        output_key='answer',\n",
    "        memory_key='chat_history',\n",
    "        chat_memory=history,\n",
    "        return_messages=True\n",
    "    )\n",
    "\n",
    "    chain = LLMChain(llm=llm, \n",
    "                    prompt=PROMPT,\n",
    "                    memory=memory\n",
    "                   #verbose=True\n",
    "                    )\n",
    "\n",
    "    output = chain.run({\"context\": relevant_docs, #\"context\": relevant_docs, \n",
    "        \"question\": question,\n",
    "        })"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "%pip install azure-cosmos"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'output' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[1], line 1\u001b[0m\n\u001b[1;32m----> 1\u001b[0m output\n",
      "\u001b[1;31mNameError\u001b[0m: name 'output' is not defined"
     ]
    }
   ],
   "source": [
    "output"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
